These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6802879)

  • 1. Effect of height and weight on the in vivo recovery of transfused factor VIII C.
    Aronstam A; McLellan DS; Wassef M; Mbatha PS
    J Clin Pathol; 1982 Mar; 35(3):289-91. PubMed ID: 6802879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 'in vivo' survival characteristics of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects.
    McLellan DS; Pelly C; McLellan HG; Jones P; Aronstam A
    Thromb Res; 1982 Jan 1-15; 25(1-2):33-9. PubMed ID: 6801811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danazol in Indian haemophiliacs.
    Sundar S; Moorleedhur-Singh GS; Dube B; Singh VP; Kumar K
    J Assoc Physicians India; 1993 Jan; 41(1):23-5. PubMed ID: 8340322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The stability of VIII:C in frozen stored plasma samples--re-examined.
    McLellan DS; Pelly C; McLellan HG; Aronstam A
    Clin Lab Haematol; 1983; 5(2):197-201. PubMed ID: 6411419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII procoagulant antigen recovery is a dose-related response to Factor VIII concentrate infusions.
    Taylor L; Ekert H; Dean F
    Haemostasis; 1984; 14(4):296-301. PubMed ID: 6437942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slow thaw siphon technique for cryoprecipitate production.
    Chudgar UH; Chandy M; Pulimood RB; Khanduri U
    Indian J Med Res; 1989 Aug; 90():295-9. PubMed ID: 2516011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of a single administration of cryoprotein and plasma on factor VIII in hemophilia A].
    Vlcková M; Vorlová Z
    Vnitr Lek; 1980 Nov; 26(11):1101-6. PubMed ID: 6789551
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro and in vivo recovery of cryoprecipitated factor 8.
    Verstraete M; Lust A; Vermylen J
    Bibl Haematol; 1970; 34():9-17. PubMed ID: 5436359
    [No Abstract]   [Full Text] [Related]  

  • 10. Low recovery in vivo of highly purified factor VIII in patients with hemophilia.
    Manno CS; Butler RB; Cohen AR
    J Pediatr; 1992 Nov; 121(5 Pt 1):814-8. PubMed ID: 1432437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV; Silva IA; Borrasca AL
    Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
    Prowse CV
    Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia.
    Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J
    Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune response induced by porcine factor VIII in severe hemophiliacs with antibody to F VIII.
    Verroust F; Allain JP
    Thromb Haemost; 1982 Oct; 48(2):238. PubMed ID: 6817447
    [No Abstract]   [Full Text] [Related]  

  • 15. New alternatives and strategies in the treatment of inhibitors.
    Hoyer LW
    Prog Clin Biol Res; 1984; 150():367-72. PubMed ID: 6431440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methods of plasma volume determination for dose calculation of factor VIII in patients with classic haemophilia.
    Ockelford PA; Lowe G; Johns AS; Berry EW
    N Z Med J; 1986 Feb; 99(796):116-9. PubMed ID: 3081842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.
    Ehrenforth S; Kreuz W; Funk M; Auerswald G; Scharrer I
    Thromb Haemost; 1994 Nov; 72(5):784-5. PubMed ID: 7900088
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inhibitors and "bypass" therapy in hemophilia].
    Fukutake K; Fukutake K
    Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034
    [No Abstract]   [Full Text] [Related]  

  • 19. Porcine factor VIII: preparation and use in treatment of inhibitor patients.
    Kernoff PB
    Prog Clin Biol Res; 1984; 150():207-24. PubMed ID: 6431429
    [No Abstract]   [Full Text] [Related]  

  • 20. [In-vivo control of blood coagulation fractions].
    Richter K; Rex JO; Stinner G; Fünfhausen G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):344-8. PubMed ID: 4195280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.